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Bullous Pemphigoid:  
A Prototypical Antibody-Mediated 
Organ-Specific Autoimmune Disease
Cassian Sitaru1
Bullous pemphigoid (BP) is a prototypical organ-specific autoimmune disease. 
Autoantibodies unfold their blister-inducing potential by triggering an fcγ-
dependent inflammatory reaction. The study by Iwata et al. in this issue provides 
the first direct evidence that IgG autoantibodies from BP patients may also weaken 
cell–matrix adhesion by depleting BP180/type XVII collagen from cultured kerati-
nocytes. These novel findings shed new light on additional mechanisms of blister 
formation in pemphigoid diseases and open the way for further informative studies.
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Bullous pemphigoid (BP) is a sub-
epidermal blistering disease that 
typically affects the elderly and is 
associated with an autoimmune 
response against hemidesmosomal 
proteins (Liu and Diaz, 2001; Mihai 
and Sitaru, 2007; Olasz and Yancey, 
2008). Extensive clinical and experi-
mental evidence strongly suggests 
that autoantibodies cause the pathol-
ogy in this disease (Sitaru and Zillikens, 
2005; Leighty et al., 2007). Circulating 
autoantibodies in BP patients exhibit 
a heterogeneous specificity to several 
hemidesmosomal components, includ-
ing BP230, an intracellular constituent 
of the hemidesmosomal plaque, and 
the transmembrane protein BP180/
type XVII collagen (Sitaru and Zillikens, 
2005; Leighty et al, 2007). Mutations 
in COL17A1 in patients with general-
ized atrophic benign epidermolysis 
bullosa and in knockout mice result 
in low or absent expression of BP180/
type XVII collagen and subepidermal 
blistering (McGrath et al., 1995; Nishie 
et al., 2007). These findings suggest 
that a decrease in the expression of this 
hemidesmosomal antigen may weaken 
cell–matrix adhesion in the skin and 
eventually result in dermal–epidermal 
separation.
Autoantibodies to the transmem-
brane antigen BP180, but not to the 
intracellularly located BP230, were 
hypothesized to be pathogenically rel-
evant (Liu and Diaz, 2001; Sitaru and 
Zillikens, 2005). Indeed, experimental 
evidence generally supports the patho-
genic role of autoantibodies to BP180 
for blister formation. IgG autoantibod-
ies, affinity purified against recombi-
nant BP180 from patients with BP and 
pemphigoid gestationis, induce der-
mal–epidermal separation in cryosec-
tions of human skin when co-incubated 
with leukocytes from healthy donors 
(Sitaru and Zillikens, 2005). In 1993, 
Liu et al. first provided evidence for a 
pathogenic role of autoantibodies to 
type XVII collagen/BP180 in vivo (Liu 
et al., 1993). The authors demonstrated 
that rabbit antibodies generated against 
murine BP180 induce subepidermal 
blisters when passively transferred 
into neonatal mice. More recently, 
further animal models reproduc-
ing blister formation in BP have been 
developed using mice that express the 
human form of the BP180 antigen 
injected with BP patient autoantibod-
ies. Studies performed mainly with 
the experimental model developed by 
Liu et al. (1993) revealed that subepi-
dermal blistering triggered by rabbit 
IgG specific to murine BP180 depends 
on complement activation, mast cell 
degranulation, macrophage activation, 
and neutrophilic infiltration. Reactive 
oxygen species and proteases, such as 
gelatinase B/MMP-9 and elastase, are 
critically involved in blister formation 
in vivo and in vitro (Liu and Diaz, 2001; 
Liu, 2004; Sitaru and Zillikens, 2005; 
Leighty et al., 2007). These findings par-
tially match the pathology observed in 
BP patients and support the prevailing 
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view that triggering an Fcγ-dependent 
inflammatory reaction is necessary for 
blister induction by autoantibodies in 
BP (Figure 1).
Although the description of the rela-
tively uncommon variant of BP with a 
paucicellular dermal infiltrate suggested 
the existence of alternative noninflam-
matory mechanisms of blister forma-
tion, until now experimental data did 
not support this hypothesis. A further 
hint that a full inflammatory response 
may not be required for subepidermal 
blistering by autoantibodies against 
BP180/type XVII collagen was provided 
by Yamamoto et al. (2002). They dem-
onstrated that rabbit antibodies gener-
ated against hamster BP180 induced 
subepidermal blisters when passively 
transferred into neonatal hamsters. The 
blister formation in this model neces-
sitates complement activation, but not 
the recruitment and activation of leuko-
cytes (Yamamoto et al., 2002).
In this issue, Iwata et al. show that 
IgG autoantibodies from patients with 
BP deplete keratinocytes of BP180/
type XVII collagen. When IgG from BP 
patients was added to cultured kera-
tinocytes, the authors found that this 
treatment depleted BP180, but not 
α6β4 integrin, from cells as assessed 
by densitometric analysis of immuno-
blots. In addition, keratinocytes treated 
with IgG from BP patients showed a 
reduction in their adhesive strength as 
revealed by a standardized detachment 
assay (Iwata et al., 2009).
These findings describe new and 
potentially relevant mechanisms of 
blistering in BP and may have impor-
tant consequences for the development 
of new treatment modalities. The fact 
that autoantibodies from patients with 
BP deplete BP180 from keratinocytes 
strongly suggests that alternative nonin-
flammatory mechanisms contribute to 
blister formation in the pemphigoid dis-
eases. Animal models of BP allow the 
in vivo relevance of these findings to be 
addressed and the relative contributions 
of the noninflammatory and inflamma-
tory mechanisms of blister formation by 
autoantibodies to be dissected.
Autoantibodies in BP are thought to 
be heterogeneous with respect to their 
blister-inducing potential. Major intrin-
sic determinants of autoantibody patho-
genicity include their specificity and 
their ability to activate complement and 
leukocytes (Sitaru and Zillikens, 2005). 
Future research should answer the 
question of whether the specificity of 
antigen-depleting autoantibodies differs 
when compared with that of autoanti-
bodies that activate putative inflamma-
tory mechanisms. BP autoantibodies 
belong to different isotypes, which may 
be associated with distinct effector func-
tions. On the basis of previous experi-
mental evidence, it has been proposed 
that blistering is induced primarily by 
IgG1, whereas IgG4 autoantibodies are 
less pathogenic or even protective (Liu, 
2002; Sitaru et al., 2007). In light of the 
novel noninflammatory mechanisms of 
blister formation by autoantibodies as 
suggested by the study by Iwata et al. 
(2009), the role of different isotypes of 
autoantibodies in the pathogenesis of 
BP requires reappraisal.
In conclusion, this study strongly 
suggests the existence of noninflamma-
tory mechanisms of blister formation 
by autoantibodies in BP. Further explo-
ration of this line of research should 
provide relevant mechanistic insights 
into BP pathogenesis and greatly facili-
tate the development of more effective 
therapeutic approaches.
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figure 1. Mechanisms of blister formation in bullous pemphigoid (BP). The left lower panel illustrates 
several structural proteins of the epidermal basement membrane that function as major autoantigens in 
autoimmune subepidermal bullous skin diseases. The main autoantigens in BP patients include the BP 
antigen 230 (BP230) and the BP antigen 180 (BP180)/type XVII collagen. BP autoantibodies accumulate 
in tissue and bind to antigens at the epithelial basement membrane. Binding of pathogenic autoantibodies 
triggers an inflammatory reaction, including fixation of complement and Fc-dependent activation of 
leukocytes. In addition to granulocytes, mast cells likely contribute to the antibody-induced inflammation 
at the dermal–epidermal junction. Activated granulocytes release reactive oxygen intermediates and 
proteases, leading to epithelial damage and blister formation. Alternatively, as shown by Iwata et al. 
(2009), IgG autoantibodies may deplete BP180 from basal keratinocytes and thus contribute to blister 
formation. LN 332, laminin 332; ROS, reactive oxygen species.
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Antimicrobial Peptides  
and Suppression of Apoptosis  
in Human Skin
Michael Zasloff1
Antimicrobial peptides (AMPs) provide broad spectrum antimicrobial defense in 
both healthy and injured skin.  At high concentrations AMPs can damage normal 
human cells, resulting in necrosis or apoptotic death. In this issue Chammoro et al. 
(2009) describe a novel mechanism involving prostaglandin PGE2 that appears to 
explain how the keratinocyte, which secretes AMPs, can remain immune to self-
inflicted AMP-induced apoptosis.  
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microbial assault (Aberg et al., 2008). 
We also know that AMPs exhibit prop-
erties that would appear to help coordi-
nate the repair of a damaged epithelium. 
These include chemoattractant, growth 
stimulatory, and angiogenic activities 
(Gallo, 2008). We have learned that 
sunlight induces keratinocytes to pro-
duce cathelicidin (also called LL-37) via 
a vitamin D–mediated circuit, explain-
ing the efficacy of photo therapy in the 
treatment of cutaneous tuberculosis 
(Zasloff, 2006). In atopic dermatitis, epi-
dermal AMP expression is depressed, 
likely resulting from the inhibitory 
effects of atopic cytokines on the expres-
sion of several AMP genes, increasing 
the risk of secondary bacterial infections 
(Gallo, 2008). In contrast, in psoriasis 
a massive overexpression of numerous 
AMPs occurs, which helps explain the 
remarkable absence of infection in this 
condition despite the damaged skin 
(Harder and Schroder, 2005). In psoria-
sis, the overexpression of LL-37 has been 
suggested to play a role, in that cellular 
DNA, in complex with LL-37, appears 
to be an especially potent inducer of 
interferon-α by epidermal dendritic cells 
(Lande et al., 2007).
Most AMPs exert antimicrobial activ-
ities by damaging membranes in target 
organisms (Zasloff, 2002). AMPs, which 
are positively charged amphi pathic 
molecules, interact most avidly with 
membranes that expose anionic phos-
pholipid headgroups on the outer sur-
face of the bilayer, a design feature that 
characterizes many species of bacteria. 
In contrast, most cells that comprise 
multicellular animals are resistant to 
AMPs at their microbicidal concentra-
tions, because the anionic phospho-
lipids of these cells are segregated to 
the cytoplasmic surface of the plasma 
membrane and within the membranes 
of intracellular organelles, including the 
bacteria-like mitochondria.
However, at higher concentra-
tions, AMPs can damage eukaryotic 
cells because of their fundamental 
amphipathic design (Zasloff, 2002; 
Barlow et al., 2006). In some contexts, 
AMPs can physically disrupt the plasma 
membrane, creating “holes” of various 
dimensions and rapidly causing “necrot-
ic” cellular death. Alternatively, AMPs 
can induce apoptosis in certain cells 
at concentrations that do not destroy 
the plasma membrane (Barlow et al., 
2006). For example, the presence of 
AMP-specific receptors on the plasma 
membrane of a cell could encourage 
localized concentration of the peptide 
ligand within the membrane. If pep-
tides were then to transverse the plasma 
membrane and enter the cytoplasm, they 
would necessarily distribute to intra-
cellular sites with high surface concen-
trations of anionic phospholipids, such as 
mitochondria. As they do with microbes, 
AMPs can damage the integrity of 
Over the past several years, we have 
developed a picture of how endog-
enous antimicrobial peptides (AMPs) 
contribute to the health of human skin. 
We know that AMPs provide human 
epidermis with anti-infective defenses 
against bacteria, fungi, protozoa, and 
viruses (Zasloff, 2002). The major AMPs 
in human epidermis are synthesized by 
keratinocytes in the stratum granulosum, 
packaged along with complex lipids in 
lamellar bodies, and delivered into the 
stratum corneum, where they help to 
maintain a barrier against water loss and 
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